166 related articles for article (PubMed ID: 21996952)
1. [Chemotherapy in elderly patients with hematological malignancies].
Ohnishi K
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
[TBL] [Abstract][Full Text] [Related]
2. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly.
Ohta M
Geriatr Gerontol Int; 2009 Jun; 9(2):115-23. PubMed ID: 19740353
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
Kuendgen A; Germing U
Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy in the elderly].
Furue H
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1796-800. PubMed ID: 1519923
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H;
Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471
[TBL] [Abstract][Full Text] [Related]
7. [Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment].
Wedding U; Bokemeyer C; Meran JG; ; ;
Med Klin (Munich); 2003 Apr; 98(4):193-207. PubMed ID: 12715143
[TBL] [Abstract][Full Text] [Related]
8. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
9. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
10. [Risk Assessment of Hematologic Malignancy Treatment of the Elderly].
Sasaki H; Takamatsu Y
Gan To Kagaku Ryoho; 2018 Jan; 45(1):16-19. PubMed ID: 29362299
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Ravandi F; Talpaz M; Estrov Z
Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
[TBL] [Abstract][Full Text] [Related]
12. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma.
Arimori S; Nagao T; Shimizu Y; Watanabe K; Komatsuda M
Tokai J Exp Clin Med; 1980 Jan; 5(1):63-71. PubMed ID: 6930119
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of elderly patients with hematological malignancies].
Saito H; Mizoguchi H
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1801-7. PubMed ID: 1381569
[TBL] [Abstract][Full Text] [Related]
16. [Hematologic malignancies/pediatric malignancies].
Usui N
Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
[No Abstract] [Full Text] [Related]
17. [Oral molecular targeting agents in hematological malignancy].
Wakabayashi S; Ohashi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1214-8. PubMed ID: 20647701
[TBL] [Abstract][Full Text] [Related]
18. Application of vitamin D and derivatives in hematological malignancies.
Kim M; Mirandola L; Pandey A; Nguyen DD; Jenkins MR; Turcel M; Cobos E; Chiriva-Internati M
Cancer Lett; 2012 Jun; 319(1):8-22. PubMed ID: 22193723
[TBL] [Abstract][Full Text] [Related]
19. [Cancer chemotherapy in patients of advanced age (over 75)].
Sasaki T; Maeda Y; Sato A; Kurihara M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):973-9. PubMed ID: 9644309
[TBL] [Abstract][Full Text] [Related]
20. [Optimising therapy in patients with haematological malignancies].
Dumontet C
Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
